Lataa...
Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia
Optimal conditioning chemotherapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains uncertain. Myeloablative regimens such as fludarabine/busulfan are favored over reduced-intensity fludarabine/melphalan (Flu/Mel); however, it is not known if Flu/Mel is inferi...
Tallennettuna:
| Julkaisussa: | Leuk Lymphoma |
|---|---|
| Päätekijät: | , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7771324/ https://ncbi.nlm.nih.gov/pubmed/32133897 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1731498 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|